Odyssey Therapeutics (ODTX.US) Debuts on US Stock Market with Stable Opening Price

On Friday, Odyssey Therapeutics (ODTX.US) debuted on the US stock market with little fluctuation in its opening price, at an IPO price of $18. As of press time, the stock fell over 1%, trading at $17.81. Odyssey Therapeutics is a clinical-stage biotechnology company headquartered in Boston, USA, primarily focusing on the development of drugs for autoimmune and inflammatory diseases. The company's core product is OD-001, a small molecule drug for treating ulcerative colitis, which has now entered the mid-stage clinical trial phase. Additionally, the company has pipelines targeting multiple immunological diseases, including lupus and atopic dermatitis.